Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash from Financing Activities (2020 - 2025)

RxSight's Cash from Financing Activities history spans 6 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 64.28% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.9 million, down 98.49%, while the annual FY2025 figure was $1.9 million, 98.49% down from the prior year.
  • Cash from Financing Activities reached $1.1 million in Q4 2025 per RXST's latest filing, up from -$530000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $120.5 million in Q3 2021 to a low of -$8.2 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $16.5 million, with a median of $1.6 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: soared 231721.15% in 2021, then crashed 1709.67% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $404000.0 in 2021, then surged by 1461.14% to $6.3 million in 2022, then plummeted by 43.52% to $3.6 million in 2023, then decreased by 16.45% to $3.0 million in 2024, then tumbled by 64.28% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Cash from Financing Activities are $1.1 million (Q4 2025), -$530000.0 (Q3 2025), and $2.1 million (Q2 2025).